NCT02915445: EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer

NCT02915445
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: EpCAM+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 65 Years (Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT02915445

Comments are closed.

Up ↑